Doc Code: AP.PRE.REO

PTC/SB/33 (12-08)
Approved for use through 01/31/2009. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid CMB control number.			
PRE-APPEAL BRIEF REQUEST FOR REVIEW		Docket Number (Optional)	
		0119742-002	
I hereby certify that this correspondence is being deposited with the	Application Number		Filed
United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)]	10/510,411		September 12, 2005
on	First Named Inventor		
Signature	Zaghouani		
	Art Unit Ex		xaminer
Typed or printed name	1644		Edwoldt, G.R.
Applicant requests review of the final rejection in the above-identified application. No amendments are being filed with this request.			
This request is being filed with a notice of appeal.			
The review is requested for the reason(s) stated on the attached sheet(s). Note: No more than five (5) pages may be provided.			
I am the			
applicant/inventor.	Signature		
assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed.	David B. Fournier		
(Form PTO/SB/96)	Typed or printed name		
✓ attorney or agent of record. 51,696 Registration number	312-781-7167		
	Telephone number		
attorney or agent acting under 37 CFR 1.34.	April 30, 2009		
Registration number if acting under 37 CFR 1.34	Date		
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.			
*Total of forms are submitted.			

This collection of information is required by 35 U.S.C. 122. The information is required to data or retain a benefit by the public which is to file (and by the USPTC to process) an application. Confidentially is governed by 36 U.S.C. 122 and 17 CPR 11.11, 14.1 At 18.1 The includedine is estimated to take of Terminary to the process of the process of

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Habib Zaghouani Appl. No.: 10/510,411

Conf. No.: 8513

Filed: September 12, 2005

Title: METHODS AND COMPOSITIONS FOR TREATMENT, PREVENTION.

SUPPRESSION, AND/OR DELAYING THE ONSET OF TYPE 1 DIABETES
Art Unit: 1644

Examiner: Edwoldt, G.R.

Docket No.: 0119742-00002

Mail Stop AF

Commissioner for Patents

Alexandria, VA 22313-1450

PRE-APPEAL BRIEF REQUEST FOR REVIEW

Claims 47-48 and 51-61 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over WO 98/30706 in view of Liu et al. (1992) PNAS 97(26): 283-292 ("Liu"). According to the Office Action, it would have been obvious to one of ordinary skill in the art, at the time the invention was made, to produce the construct of WO 98/30706 employing the T-cell epitopes of SEQ ID NOs: 3 and 4, as taught by Liu (Office Action at page 2). Applicants respectfully traverse this rejection.

As set forth at pages 2-6 of the Office Action response dated January 28, 2009, no *prima* facie case of obviousness has been established at least because: (1) Liu teaches away from the presently claimed invention; and (2) no reasonable expectation of success has been established.

Conclusion

The application is believed to be in condition for allowance. Early and favorable considerations is respectfully requested.

Respectfully submitted,

K&L GATES LLP/ David B. Fournier

Reg. No. 51,696